Zhejiang Langhua Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise integrating R & D, production and trade. As a subsidiary of Weiya biotechnology holding group, a leading enterprise in the field of innovative drug discovery, Langhua is committed to providing global partners with high-efficiency, flexible and high-quality cdmo one-stop solutions for small molecule drugs, from APIs to preparations, from preclinical to commercial supply, covering the whole life cycle of drugs, At the same time, it provides high-quality small molecule imitation APIs for the global market. It is the main manufacturer of global quinolones, spironolactone, olanzapine, antiviral and other APIs. Ningbo noble Pharmaceutical Co., Ltd., formerly known as the pharmaceutical division of zhongninghua group, has more than 30 years of international market development experience. In 2018, it became a wholly-owned subsidiary of Langhua pharmaceutical, focusing on the operation of pharmaceutical intermediates, APIs, preparations, medical devices and other products, and providing global customers with high-quality pharmaceutical products and services. After more than ten years of development, Langhua has established a perfect quality management system and EHS management system, and has a domestic leading API and preparation R & D technology platform. Deeply involved in the listing process of more than 20 new drugs, the product line covers cancer, AIDS, diabetes, cardiovascular and other fields, and has a good delivery record. Langhua has successively passed the audit and certification of nmpa, FDA, EDQM, PMDA, Anvisa, who and other authoritative institutions, and passed the PSCI audit. It has long provided high-quality products and services for global new drug R & D institutions and multinational pharmaceutical companies, so that patients can buy and afford urgently needed drugs and contribute to human health.